Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :4991
Small font sizeDefault font sizeIncrease font size
Navigate here
  Next article
  Previous article 
  Table of Contents
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (522 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded341    
    Comments [Add]    
    Cited by others 2    

Recommend this journal


Year : 2010  |  Volume : 47  |  Issue : 1  |  Page : 73-74

Protracted cisplatin-induced vomiting responding to mosapride

1 Department of Medical Oncology, Dr. B.R.A. Institute, Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029, India
2 Department of Radiation Oncology, Dr. B.R.A. Institute, Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029, India

Date of Web Publication12-Jan-2010

Correspondence Address:
A Sharma
Department of Medical Oncology, Dr. B.R.A. Institute, Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.58866

Rights and Permissions

How to cite this article:
Ganesan P, Sharma A, Mohanti B K, Gogia A. Protracted cisplatin-induced vomiting responding to mosapride. Indian J Cancer 2010;47:73-4

How to cite this URL:
Ganesan P, Sharma A, Mohanti B K, Gogia A. Protracted cisplatin-induced vomiting responding to mosapride. Indian J Cancer [serial online] 2010 [cited 2022 Aug 13];47:73-4. Available from:


Acute vomiting (onset: within 24 hours) and delayed vomiting (onset after 24 hours, resolution by one week) are well described complications of cisplatin. [1] A syndrome of "prolonged vomiting" lasting more than two weeks after chemotherapy has been described. [2] We encountered a patient of nasopharyngeal carcinoma who developed prolonged vomiting after cisplatin and concurrent radiation therapy.

A 35-year-old female with nasopharyngeal carcinoma (T2N2M0, stage III) received two cycles of Paclitaxel and Carboplatin, followed by concurrent chemoradiation (70 Gray with seven doses cisplatin 40 mg/m 2 /week). Antiemetic support (starting from day one of each cycle) included ondansetron (8 mg TID for three days), metoclopramide (10 mg TID for three days), and dexamethasone (4 mg TID for three days). She developed acute grade 3 emesis (NCI CTC v3.0 - required IV fluids for 48 hours) after the fourth dose of cisplatin, so aprepitant (125 mg PO D1, 80 mg PO D2, and D3) was added from the next cycle. The fifth and sixth doses were well tolerated. Forty-eight hours after the seventh dose of cisplatin she developed Grade 4 nausea and vomiting and presented with dehydration, hypokalemic alkalosis, and symptomatic hypocalcemia (carpopedal spasms). The deficits were corrected with intravenous fluids and electrolyte supplements (potassium, calcium, and magnesium), but the vomiting could not be controlled with dexamethasone (4 mg IV eight hourly), metoclopramide (20 mg IV six hourly), and lorazepam (1 mg PO TID).

Two weeks after chemoradiation was stopped, the vomiting (nonprojectile, nonbilious, containing undigested food particles and occurring within half hour of food intake) persisted and she remained dependent on parenteral support. She complained of tingling sensations over her fingers and toes (grade 1 neuropathy), but tendon jerks were diminished. A computed tomography (CT) scan of the brain was normal. Renal and liver function, electrolytes (including magnesium and calcium), blood gases, and hematologic parameters had normalized post admission. There was no intestinal dilation on abdominal radiography and no abnormality was noted on gastroduodenoscopy or abdominal sonography. Studies for gastric emptying could not be done.

Gastric outlet obstruction was suggested by the clinical presentation, but there was no demonstrable lesion. Gastric paresis was considered and Tab. Mosapride 5 mg TID was started (subsequently increased to 10 mg TID). Vomiting decreased rapidly and within 72 hours she was able to tolerate oral diet. Within seven days of starting Mosapride she was discharged on a normal diet. She completed her radiotherapy course without further issues. Mosapride was continued in the same dose during this period.

Chemotherapy-induced delayed vomiting usually resolves within one week. Other causes must be considered in any vomiting lasting beyond one week. "Prolonged vomiting" is not a widely used term, but symptoms lasting for more than two weeks after completion of chemotherapy have been thus described. [2] Gastric paresis may be one of the causes of prolonged vomiting and has also been described after cisplatin use, where it has been seen as a part of autonomic neuropathy (cumulative dose of cisplatin (560 mg/m 2 ). [2],[3]

Our patient had sensory neuropathy, but had no features of dysautonomia. Although the cumulative dose of cisplatin in our patient was only 280 mg/m 2 , previous treatment with neurotoxic drugs (paclitaxel), absence of other causes, and prompt response to prokinetic agents argue toward the possibility of cisplatin-induced autonomic neuropathy leading to gastric paresis in this patient. Prompt recognition of this entity and early treatment with prokinetic agents might avoid much patient distress.

  References Top

1.Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS. Incidence, Course, and Severity of Delayed Nausea and Vomiting Following the Administration of High-Dose Cisplatin. J Clin Oncol 1985;3:1379-84.  Back to cited text no. 1      
2.Hecht JR, Lembo T, Chap L. Prolonged Nausea and Vomiting after High Dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation in the Treatment of High Risk Breast Carcinoma. Cancer 1997;79:1698-702.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Cohen SC, Mollman JE. Cisplatin-induced gastric paresis. J Neurooncol 1987;237-40  Back to cited text no. 3      

This article has been cited by
1 Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial
Jinwei Xie, Yingchun Cai, Jun Ma, Qiang Huang, Fuxing Pei
BMC Anesthesiology. 2020; 20(1)
[Pubmed] | [DOI]
2 Looking beyond 5-HT3 receptors: A review of the wider role of serotonin in the pharmacology of nausea and vomiting
Kevin D. Johnston,Zengbing Lu,John A. Rudd
European Journal of Pharmacology. 2014;
[Pubmed] | [DOI]


Print this article  Email this article
Previous article Next article


  Site Map | What's new | Copyright and Disclaimer | Privacy Notice
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow